Persistent Postural-Perceptual Dizziness

Persistent postural-perceptual dizziness (PPPD) is a condition in which dizziness, unsteadiness, or a non-spinning sensation persists for three months or more, even after the original problem that caused it has resolved. Most patients describe feeling unsteady when standing or walking, disorientated in busy visual environments (supermarkets, crowded streets, watching screens), and worse with movement — particularly riding in cars, looking up at shelves, or turning their head quickly.

Crucially, PPPD is not "all in the head" in any dismissive sense. It's a recognised disorder of how the brain processes balance signals, often triggered by a definite event such as an inner-ear infection, a panic attack, or a mild head injury. The patient's balance system gets stuck in a hypervigilant state — like a smoke detector that won't reset after a small fire.

The good news is that PPPD responds to treatment: a combination of specialised physiotherapy (vestibular rehabilitation), a talking therapy called cognitive behavioural therapy (CBT), and sometimes a low dose of an antidepressant medicine such as sertraline. The antidepressant isn't used because the patient is depressed but because these medicines also help reset the balance system. Recovery is usually gradual but substantial.

PPPD is a functional vestibular disorder formally defined by the Bárány Society in 2017.1 The 2017 criteria unified four previously separate clinical entities — phobic postural vertigo (Brandt & Dieterich, 1986), space-motion discomfort, visual vertigo, and chronic subjective dizziness — under a single diagnostic framework grounded in a common mechanism: maladaptive plastic changes in postural control and visual-vestibular processing.3,2

The disorder is functional in the modern neurological sense — meaning that it produces real, measurable changes in brain function (the Indovina 2015 fMRI work showed insular hypoconnectivity in PPPD patients during vestibular stimulation) without an identifiable structural lesion.7"Functional" in this connotation explicitly does not mean psychogenic or psychosomatic; it means a problem with how the system is operating rather than with the hardware.

Epidemiologically, PPPD is precipitated by a definable event in essentially every case. The precipitant distribution is approximately:1,2

• Peripheral vestibular conditions (BPPV, vestibular neuritis, Ménière's) — 25%
• Vestibular migraine — 15–20%
• Psychiatric conditions (panic attack, generalised anxiety) — 15–25%
• Mild traumatic brain injury — 10–15%
• Dysautonomia or other medical illness — 5–10%
• Multiple sequential precipitants — disproportionately likely to develop PPPD

The Gabacorta 2022 finding that 22% of patients with two or more episodic vestibular conditions develop PPPD, versus 4% of those with a single condition, suggests that cumulative vestibular insults predispose to the maladaptive plasticity that underlies the disorder.6

The clinical importance of PPPD lies in recognising that many patients with apparently "treatment-refractory" vestibular disorders are actually presenting with two conditions: the original peripheral or central vestibulopathy that triggered PPPD, and the PPPD itself. Continued vestibular suppressants, repeated investigations, and escalating symptom-focused interventions worsen rather than help — they reinforce the maladaptive postural and visual-dependent strategies that underlie the chronic symptoms.

Two corollaries matter operationally. First, vestibular suppressant medications (benzodiazepines, meclizine, prochlorperazine, betahistine) are useful in the acute phase of vestibular illness but are actively harmful in the chronic phase — they prevent central compensation, perpetuate visual dependence, and confound the natural resolution of vestibular symptoms. Many PPPD patients arrive in tertiary clinics on chronic vestibular suppressants prescribed years earlier; withdrawal is often the first therapeutic step.2

Second, repeated negative investigations — multiple MRIs, repeated audiometry, repeated VNG — reinforce rather than reassure. The clinician's task is to make a positive diagnosis of PPPD, explain the model to the patient (the "balance system stuck in alarm mode" metaphor works in clinic), and direct the patient to evidence-based intervention. Investigation proportional to the clinical question is fine; investigation as anxiolytic is iatrogenic.

To meet the formal criteria for PPPD, a patient needs all five of the following:

• Dizziness, unsteadiness, or non-spinning vertigo on most days for 3 months or more;
• Symptoms made worse by all three of: standing up, moving (the patient or what they are looking at), and busy or moving visual environments;
• A precipitating event — usually a vestibular illness, a head injury, a panic attack, or another medical problem;
• Significant distress or impact on daily life;
• No other condition that better explains the symptoms.

If a patient has all the features but only for six weeks, they don't yet meet the criteria — but they should be identified as at-risk and started on early intervention to prevent crystallisation into the full disorder.

The five PPPD criteria (Staab 2017) — exactly as applied by the criteria checker above — are:1

1. A. One or more symptoms of dizziness, unsteadiness, or non-spinning vertigo are present on most days (≥ 15 days/month) for ≥ 3 months. Symptoms typically last for prolonged periods (hours to all day) but may wax and wane in severity.
2. B. Persistent symptoms occur without specific provocation, but are exacerbated by:
   1. upright posture,
   2. active or passive motion without regard to direction or position, and
   3. exposure to moving visual stimuli or complex visual patterns.
   All three exacerbators must be present.
3. C. The disorder is precipitated by conditions that cause vertigo, unsteadiness, dizziness, or problems with balance, including acute, episodic, or chronic vestibular syndromes; other neurological or medical illnesses; or psychological distress.
4. D. Symptoms cause significant distress or functional impairment.
5. E. Symptoms are not better accounted for by another disease or disorder.

Three operational points. First, criterion B's three exacerbators are conjunctive— all three are required. Missing the visual component (motion-rich environments like supermarkets, scrolling on phones, busy patterns) is a common reason for missed diagnosis. Second, the duration threshold of 3 months separates PPPD from sub-threshold or evolving forms — patients with the right phenotype but only 4–8 weeks of symptoms benefit from early intervention but do not yet have the diagnosis. Third, the exclusion criterion is permissive — PPPD can and does coexist with vestibular migraine, BPPV, or Ménière's; co-diagnose where criteria for both are met.2

Three diagnostic refinements at the clinician level. First, the "motion intolerance" component of criterion B is broader than many clinicians initially appreciate — it includes self-motion (walking, head movement) and external motion (passenger in a car, escalators, watching moving objects). Asking specifically "is being a passenger in a car worse than driving?" often unlocks the visual-vestibular conflict pattern.

Second, visual dependence is the most diagnostically distinctive feature of PPPD and is captured by the visual-stimuli component of criterion B. The classic clinical questions: "is it worse in supermarkets?", "is it worse on patterned carpets?", "does scrolling on your phone make it worse?", "is it worse with crowds walking past you?". Affirmatives to two or more of these strongly suggest visual dependence and PPPD even before applying the full criteria framework.

Third, the criterion E exclusion is more permissive than criterion E in the vestibular migraine criteria. PPPD frequently coexists with an active vestibular disorder — vestibular migraine is the most common co-diagnosis, with rates of 30–50% in series that apply both criteria sets. Persistent symptoms that fit PPPD between vestibular migraine attacks are an additional disease, not a recharacterisation of the migraine. Both should be diagnosed and both should be treated.6

After an inner-ear or balance problem, the brain has to adapt to the new information it's getting. Normally, this adaptation happens automatically within weeks. In PPPD, the adaptation gets stuck in a particular pattern: the brain becomes over-reliant on what the eyes are seeing to maintain balance, and it stays in "high alert" even when there's no longer a real problem.

This explains the characteristic symptom pattern. Standing up activates the balance system, so it's worse than sitting. Movement — your own or things you're looking at — challenges the system, so it's worse. Busy visual environments overload the visual processing the brain has come to depend on, so they're worst of all.

The mechanism of PPPD is best understood as a maladaptive plastic change in postural control and multisensory integration following a precipitating vestibular, neurological, or psychiatric insult. Three interacting changes characterise the chronic state:

• Visual dependence: down-weighting of vestibular and proprioceptive inputs in favour of visual inputs for postural control. Adaptive in the acute phase (when vestibular signals are unreliable), maladaptive when persisted.
• High postural control gain: stiff, ankle-strategy postural control with increased muscle co-contraction. Visible on posturography as increased sway amplitude with paradoxical hypersensitivity to perturbation.
• Hypervigilance and threat appraisal: the brain's threat-evaluation systems (insula, amygdala) remain activated by vestibular signals long after the original threat has resolved. The fMRI evidence supports altered functional connectivity between the insula and central vestibular networks.7

The precipitating events that trigger this maladaptation fall into four broad categories with roughly equal contribution to the population of PPPD patients:1,2

• Vestibular: BPPV, vestibular neuritis, Ménière's, vestibular migraine — the trigger is a genuine vestibular event that resolves but leaves PPPD behind.
• Neurological: mild traumatic brain injury, stroke (particularly small posterior fossa events), demyelinating disease.
• Medical: orthostatic intolerance, POTS, autonomic dysfunction.
• Psychiatric: panic attack, generalised anxiety disorder, depressive episode — particularly when accompanied by autonomic symptoms that the patient experiences as dizziness.

Common features predicting evolution from acute illness to PPPD include high pre-morbid trait anxiety, prior anxiety or depressive disorders, female sex, and — most strongly — multiple sequential vestibular insults. The clinical implication is that early intervention in high-risk patients (those with these predictors and ongoing symptoms beyond 4–6 weeks post-trigger) may prevent crystallisation into full PPPD.6

The functional-not-psychogenic distinction deserves careful clinician-level framing. PPPD is mechanistically distinct from somatisation, conversion disorder, and anxiety-driven dizziness, even though it can coexist with all three and shares some risk factors. The functional model — maladaptive plasticity in a real neurological system, demonstrable on fMRI and posturography — gives the clinician a positive, mechanistic explanation to offer the patient: the brain has learned the wrong response to a real triggering event, and the treatment is unlearning, not symptom suppression.2

This framing matters for two reasons. First, it makes the rehabilitation rationale comprehensible to the patient — vestibular rehabilitation works by retraining the maladaptive postural and visual-dependent strategies, not by "exercising the inner ear". Second, it de-stigmatises the diagnosis. Patients who have been told their symptoms are anxiety-driven or psychogenic often arrive defensive and treatment-resistant; reframing the problem as a learnable-and-unlearnable functional disorder unlocks engagement with therapy.

PPPD treatment combines three approaches, usually in parallel rather than sequentially. Vestibular rehabilitation is a specialised physiotherapy programme that gradually exposes the patient to the movements and visual environments that trigger their symptoms, in a structured way that helps the brain relearn proper balance processing. Cognitive behavioural therapy (CBT) helps the patient understand the condition, reduce avoidance behaviours, and manage the anxiety that often accompanies chronic dizziness. Medication — usually a low-dose SSRI such as sertraline — helps reset the hyperactive balance-threat circuits and can be very effective, particularly when combined with the other two approaches.

Recovery is usually substantial but gradual — most patients see meaningful improvement over 3–6 months of consistent treatment. The condition is not a permanent disability; with the right intervention most patients return to good function, even if some residual sensitivity to busy environments persists.

PPPD treatment is multimodal, with the strongest evidence supporting a combination of vestibular rehabilitation therapy (VRT), cognitive behavioural therapy (CBT), and serotonergic pharmacotherapy. Each component targets a different facet of the maladaptive plasticity.

Vestibular rehabilitation is the cornerstone, with the longest evidence base. PPPD-targeted VRT differs from standard VRT in its progressive graded-exposure structure: starting from positions and environments the patient currently tolerates, gradually increasing motion and visual complexity, and explicitly including provocative head movements and visual-motion exposure. Standard one-size-fits-all VRT can paradoxically worsen PPPD by triggering threat-circuit responses; a therapist experienced in PPPD-specific approaches is materially more effective than a general vestibular physiotherapist.8

Cognitive behavioural therapy addresses the catastrophising, threat-monitoring, and avoidance behaviours that maintain PPPD. The Yu 2018 RCT compared sertraline alone with sertraline plus CBT and found substantially greater improvement in dizziness handicap (DHI), anxiety (HARS), and depression (HDRS) scores in the combined group — supporting CBT as a value-adding augmentation rather than a standalone treatment.4

Serotonergic pharmacotherapy uses low-dose SSRIs or SNRIs as first-line agents. Sertraline (50–200 mg/day), escitalopram (10–20 mg/day), and venlafaxine (75 mg/day) all have supporting evidence; paroxetine has the longest track record in this indication (Horii et al. 2007).5,4 The mechanism is believed to be modulation of serotonergic projections to the vestibular nuclei and to the insular-amygdalar threat-appraisal network, rather than a primary antidepressant effect. Treatment is typically continued for 12 months minimum after symptom resolution to allow stable replasticisation.

Three things to avoid in PPPD management. Vestibular suppressants (meclizine, cinnarizine, prochlorperazine, betahistine, benzodiazepines) prevent central compensation and perpetuate symptoms — withdraw them during initial management. Repeat investigations (multiple MRIs, repeated VNG, repeated audiometry) without clear new indication reinforce the threat-monitoring pattern. Symptomatic escalation — stronger antiemetics, sedatives, surgery for incidental findings — moves the patient in the wrong direction.2

Three clinician-level refinements on the standard management framework. First, the order of initiation matters. Starting all three modalities simultaneously is impractical for most patients; the pragmatic sequence is (1) clear diagnostic explanation and rationale, (2) referral to a PPPD-experienced vestibular physiotherapist, (3) commencement of SSRI at low dose with slow titration, (4) addition of CBT when the patient is engaged and ready. Setting expectations explicitly — 3–6 months to substantial improvement, not 3–6 weeks — protects against premature discontinuation, the most common reason for apparent treatment failure.

Second, the SSRI choice and dose matter. Start lower than standard depression doses — sertraline 25 mg daily for 5–7 days then 50 mg, escitalopram 5 mg then 10 mg — and titrate slowly. Patients with PPPD are often initially intolerant of activating side effects, which can mimic or worsen their dizziness in the first 1–2 weeks. Forewarning the patient about this and offering a slow titration improves persistence substantially.5

Third, refractory PPPD deserves a systematic re-look. The most common reasons for apparent treatment failure in our experience: an undiagnosed comorbid vestibular migraine that needs its own prophylactic treatment; persistent use of vestibular suppressants that perpetuate visual dependence; insufficient duration of VRT (less than 12 weeks at adequate intensity); and unrecognised comorbid generalised anxiety disorder that would itself benefit from anxiety-specific CBT rather than PPPD-focused CBT. Refractory PPPD warrants multidisciplinary review (neurology, vestibular physiotherapy, clinical psychology) before further pharmacological escalation.6

The most recent systematic review of conservative therapy in PPPD found that VRT or CBT combined with SSRI consistently outperformed single-modality treatment on the Dizziness Handicap Inventory, the Hospital Anxiety and Depression Scale, and the Hamilton scales — consolidating the multimodal approach as standard.6